Back to search results

PRECISE-AKI for Acute Kidney Injury in Hospitalized Veterans

This study is looking at a new tool called PRECISE-AKI Clinical Decision Support Tool to help doctors better diagnose acute kidney injury (AKI) in hospitalized Veterans. AKI is a sudden loss of kidney function that affects many Veterans and can lead to serious health problems. The PRECISE-AKI tool uses artificial intelligence (AI) to help doctors figure out the specific cause of AKI, which is important for getting the right treatment. The study wants to see if this tool helps doctors make more accurate diagnoses. You might be able to join if you are 18 or older and are a hospitalized Veteran with AKI that meets certain criteria. The study is currently unclear on its recruitment status and plans to enroll 60 participants. The main goal is to see if the tool improves how often doctors order the right tests for AKI, measured up to 30 days.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It aims to enroll 60 participants, but the phase is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, appropriate diagnostic testing rates, will be measured up to 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07217808

Precision-Medicine Diagnostic Support in Hospitalized Veterans With Acute Kidney Injury

Not Yet Recruiting
NAAges 18+Interventional
VA Office of Research and Development
~60 participants
Updated 2025-10-16 on ClinicalTrials.gov
What's tested:PRECISE-AKI Clinical Decision Support Tool

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rates of Appropriate Diagnostic Testing
Measured over Up to 30 days

Conditions

Acute Kidney Injury (AKI)

Explore related trials

Acute Renal Failure

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Edward D Siew, MD MSc · PRINCIPAL_INVESTIGATOR · Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
  • Michael E Matheny, MD MS MPH · PRINCIPAL_INVESTIGATOR · Tennessee Valley Healthcare System Nashville Campus, Nashville, TN

Who to contact

Edward D Siew, MD MSc
[email protected]
(615) 343-1279
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eligible providers will be those that have at least 4 weeks of inpatient ward team or consultation team activity during a 12-month period.

Exclusion

Ineligible providers will be those that have \< 4 weeks of inpatient ward team of consultative team activity during a 12 month period.
Hospitalizations with non-persistent (\<48 hours) stage 1 injury or less.

What this trial measures

  • Rates of Appropriate Diagnostic TestingUp to 30 days

    Based on the presenting context, the investigators will compare rates of appropriate diagnostic testing between intervention and control patients among those meeting the AKI case definition